<p>Adagene Inc. 贊助的 ADR (NASDAQ:ADAG - 免費報告) - HC Wainwright 的股票研究分析師在 4 月 7 日星期二發佈的研究報告中發佈了對 Adagene 2026 財年的盈利預測。HC Wainwright 的分析師 A. He 預測該公司將在本年度每股收益為（$0.37）。Adagene 當前全年的共識盈利預測為每股（$0.60）。HC Wainwright 還發布了對 Adagene 2027 財年每股收益的預測為（$0.44），2028 財年每股收益為（$0.74），2029 財年每股收益為（$1.13）以及 2030 財年每股收益為（$0.92）。</p>
<p>ADAG 還受到其他幾份研究報告的關注。Weiss Ratings 在 1 月 21 日星期三的研究報告中重申了對 Adagene 股票的 &#34;賣出（d-）&#34;評級。華爾街 Zen 在 3 月 21 日星期六的研究報告中將 Adagene 股票的評級上調至 &#34;持有&#34;。最後，Guggenheim 在週一的研究報告中將 Adagene 股票的目標價格從 $9.00 提高至 $10.00，並給予該公司 &#34;買入&#34;評級。兩位股票研究分析師給予該股票 &#34;強烈買入&#34;評級，兩位給予 &#34;買入&#34;評級，一位給予 &#34;賣出&#34;評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 &#34;買入&#34;，共識目標價格為 $8.00。</p>
<p><strong>閲讀我們關於 Adagene 的最新股票報告</strong></p>
<h2>Adagene 股票表現</h2>
<p>NASDAQ:ADAG 的股票在星期四開盤時為 $4.00。該公司的 50 日簡單移動平均線為 $3.40，200 日簡單移動平均線為 $2.41。Adagene 的 12 個月低點為 $1.30，12 個月高點為 $4.75。</p>
<p>Adagene (NASDAQ:ADAG - 獲取免費報告) 最近在 4 月 1 日星期三發佈了季度財報。該公司報告的每股收益為（$0.04），超出分析師的共識預期（$0.28）$0.24。該季度的收入為 $3.84 百萬，而共識預期為 $17.50 百萬。</p>
<h2>Adagene 的機構交易</h2>
<p>機構投資者最近增加或減少了對該公司的持股。Marex Group plc 在第二季度購買了價值 $47,000 的 Adagene 新股份。SmartHarvest Portfolios LLC 在第四季度購買了價值約 $73,000 的 Adagene 新股份。Citadel Advisors LLC 在第三季度購買了價值約 $80,000 的 Adagene 新股份。Gordian Capital Singapore Pte Ltd 在第三季度將其在 Adagene 的持股增加了 101.4%。Gordian Capital Singapore Pte Ltd 目前擁有 48,342 股該公司的股票，價值 $96,000，此前在上個季度增持了 24,342 股。最後，Fifth Lane Capital LP 在第四季度將其在 Adagene 的持股增加了 427.3%。Fifth Lane Capital LP 目前擁有 145,000 股該公司的股票，價值 $274,000，此前在上個季度增持了 117,500 股。機構投資者持有該公司 9.51% 的股份。</p>
<h2>Adagene 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Adagene Inc. 總部位於中國蘇州，是一家臨牀階段的生物製藥公司，專注於抗體基礎治療的發現和開發，主要用於癌症和免疫相關疾病。公司成立於 2017 年，利用其專有的免疫組學技術平台挖掘人類抗體庫，並設計新型單特異性和雙特異性抗體。Adagene 的產品線包括多個處於臨牀前和早期臨牀開發階段的候選藥物，重點是針對腫瘤微環境和調節免疫檢查點以增強抗腫瘤療效。</p>
<p>Adagene 研發工作的核心是其 Bihanc™ 抗體平台，該平台結合了組合噬菌體展示、基於結構的設計和人工智能，以優化結合親和力、特異性和開發性。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Adagene</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QURBRw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QURBRw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 $1,000 在 Adagene 嗎？</h2>
<p>在你考慮 Adagene 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 Adagene 並不在名單上。</p>
<p>雖然 Adagene 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得投資。</p>
<p>在這裏查看這五隻股票</p>

天演藥業

<p>Adagene Inc.（納斯達克代碼：ADAG）收到了 HC Wainwright 對 2026 財年的收益預測，預計每股虧損為（$0.37），而市場共識預測為（$0.60）。未來的收益預測包括 2027 財年（$0.44）和 2028 財年（$0.74）。該股票目前的平均評級為 “買入”，目標價格為$8.00。最近的交易顯示，股票開盤價為$4.00，12 個月的價格區間為$1.30 至$4.75。機構投資者持有該公司 9.51% 的股份，該公司專注於癌症的抗體治療</p>

<p>Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Free Report) - Equities research analysts at HC Wainwright issued their FY2026 earnings estimates for Adagene in a research report issued on Tuesday, April 7th. HC Wainwright analyst A. He forecasts that the company will post earnings of ($0.37) per share for the year. The consensus estimate for Adagene's current full-year earnings is ($0.60) per share. HC Wainwright also issued estimates for Adagene's FY2027 earnings at ($0.44) EPS, FY2028 earnings at ($0.74) EPS, FY2029 earnings at ($1.13) EPS and FY2030 earnings at ($0.92) EPS.</p>
<div class="lb-trans"><p>Adagene Inc. 贊助的 ADR (NASDAQ:ADAG - 免費報告) - HC Wainwright 的股票研究分析師在 4 月 7 日星期二發佈的研究報告中發佈了對 Adagene 2026 財年的盈利預測。HC Wainwright 的分析師 A. He 預測該公司將在本年度每股收益為（$0.37）。Adagene 當前全年的共識盈利預測為每股（$0.60）。HC Wainwright 還發布了對 Adagene 2027 財年每股收益的預測為（$0.44），2028 財年每股收益為（$0.74），2029 財年每股收益為（$1.13）以及 2030 財年每股收益為（$0.92）。</p>
</div><p>ADAG has been the subject of several other research reports. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Adagene in a research note on Wednesday, January 21st. Wall Street Zen upgraded shares of Adagene to a &#34;hold&#34; rating in a research note on Saturday, March 21st. Finally, Guggenheim boosted their target price on shares of Adagene from $9.00 to $10.00 and gave the company a &#34;buy&#34; rating in a research note on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of &#34;Buy&#34; and a consensus target price of $8.00.</p>
<div class="lb-trans"><p>ADAG 還受到其他幾份研究報告的關注。Weiss Ratings 在 1 月 21 日星期三的研究報告中重申了對 Adagene 股票的 &#34;賣出（d-）&#34;評級。華爾街 Zen 在 3 月 21 日星期六的研究報告中將 Adagene 股票的評級上調至 &#34;持有&#34;。最後，Guggenheim 在週一的研究報告中將 Adagene 股票的目標價格從 $9.00 提高至 $10.00，並給予該公司 &#34;買入&#34;評級。兩位股票研究分析師給予該股票 &#34;強烈買入&#34;評級，兩位給予 &#34;買入&#34;評級，一位給予 &#34;賣出&#34;評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 &#34;買入&#34;，共識目標價格為 $8.00。</p>
</div><p><strong>Read Our Latest Stock Report on Adagene</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Adagene 的最新股票報告</strong></p>
</div><h2>Adagene Stock Performance</h2>
<div class="lb-trans"><h2>Adagene 股票表現</h2>
</div><p>Shares of NASDAQ:ADAG opened at $4.00 on Thursday. The company has a fifty day simple moving average of $3.40 and a 200 day simple moving average of $2.41. Adagene has a 12-month low of $1.30 and a 12-month high of $4.75.</p>
<div class="lb-trans"><p>NASDAQ:ADAG 的股票在星期四開盤時為 $4.00。該公司的 50 日簡單移動平均線為 $3.40，200 日簡單移動平均線為 $2.41。Adagene 的 12 個月低點為 $1.30，12 個月高點為 $4.75。</p>
</div><p>Adagene (NASDAQ:ADAG - Get Free Report) last issued its quarterly earnings results on Wednesday, April 1st. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.24. The company had revenue of $3.84 million during the quarter, compared to the consensus estimate of $17.50 million.</p>
<div class="lb-trans"><p>Adagene (NASDAQ:ADAG - 獲取免費報告) 最近在 4 月 1 日星期三發佈了季度財報。該公司報告的每股收益為（$0.04），超出分析師的共識預期（$0.28）$0.24。該季度的收入為 $3.84 百萬，而共識預期為 $17.50 百萬。</p>
</div><h2>Institutional Trading of Adagene</h2>
<div class="lb-trans"><h2>Adagene 的機構交易</h2>
</div><p>Institutional investors have recently added to or reduced their stakes in the business. Marex Group plc bought a new stake in Adagene during the second quarter valued at $47,000. SmartHarvest Portfolios LLC bought a new position in shares of Adagene during the fourth quarter worth about $73,000. Citadel Advisors LLC bought a new position in shares of Adagene during the third quarter worth about $80,000. Gordian Capital Singapore Pte Ltd grew its position in shares of Adagene by 101.4% during the third quarter. Gordian Capital Singapore Pte Ltd now owns 48,342 shares of the company's stock worth $96,000 after acquiring an additional 24,342 shares during the last quarter. Finally, Fifth Lane Capital LP grew its position in shares of Adagene by 427.3% during the fourth quarter. Fifth Lane Capital LP now owns 145,000 shares of the company's stock worth $274,000 after acquiring an additional 117,500 shares during the last quarter. Institutional investors own 9.51% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者最近增加或減少了對該公司的持股。Marex Group plc 在第二季度購買了價值 $47,000 的 Adagene 新股份。SmartHarvest Portfolios LLC 在第四季度購買了價值約 $73,000 的 Adagene 新股份。Citadel Advisors LLC 在第三季度購買了價值約 $80,000 的 Adagene 新股份。Gordian Capital Singapore Pte Ltd 在第三季度將其在 Adagene 的持股增加了 101.4%。Gordian Capital Singapore Pte Ltd 目前擁有 48,342 股該公司的股票，價值 $96,000，此前在上個季度增持了 24,342 股。最後，Fifth Lane Capital LP 在第四季度將其在 Adagene 的持股增加了 427.3%。Fifth Lane Capital LP 目前擁有 145,000 股該公司的股票，價值 $274,000，此前在上個季度增持了 117,500 股。機構投資者持有該公司 9.51% 的股份。</p>
</div><h2>Adagene Company Profile</h2>
<div class="lb-trans"><h2>Adagene 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Adagene Inc, headquartered in Suzhou, China, is a clinical-stage biopharmaceutical company specializing in the discovery and development of antibody-based therapeutics for cancer and immune-related diseases. Founded in 2017, the company leverages its proprietary immunome technology platform to mine human antibody repertoires and engineer novel monospecific and bispecific antibodies. Adagene's pipeline includes multiple candidates in preclinical and early clinical development, with a focus on targeting tumor microenvironments and modulating immune checkpoints to enhance anti-tumor efficacy.</p>
<div class="lb-trans"><p>Adagene Inc. 總部位於中國蘇州，是一家臨牀階段的生物製藥公司，專注於抗體基礎治療的發現和開發，主要用於癌症和免疫相關疾病。公司成立於 2017 年，利用其專有的免疫組學技術平台挖掘人類抗體庫，並設計新型單特異性和雙特異性抗體。Adagene 的產品線包括多個處於臨牀前和早期臨牀開發階段的候選藥物，重點是針對腫瘤微環境和調節免疫檢查點以增強抗腫瘤療效。</p>
</div><p>At the core of Adagene's research and development efforts is its Bihanc™ antibody platform, which combines combinatorial phage display, structure-based design and artificial intelligence to optimize binding affinity, specificity and developability.</p>
<div class="lb-trans"><p>Adagene 研發工作的核心是其 Bihanc™ 抗體平台，該平台結合了組合噬菌體展示、基於結構的設計和人工智能，以優化結合親和力、特異性和開發性。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Adagene</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Adagene</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QURBRw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=ADAG"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Adagene Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Adagene 嗎？</h2>
</div><p>Before you consider Adagene, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Adagene 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adagene wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 Adagene 並不在名單上。</p>
</div><p>While Adagene currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Adagene 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得投資。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

分析師對天演藥業 2026 財年收益的預測